<DOC>
	<DOCNO>NCT02265276</DOCNO>
	<brief_summary>Non Alcoholic Fatty Liver Disease ( NAFLD ) consider component metabolic syndrome . The prevalence increase rapidly India , along increase prevalence diabetes obesity . Insulin resistance key underlie pathogenetic mechanism NAFLD . NAFLD account significant morbidity mortality therapeutic option limit . Insulin sensitize drug use management NAFLD .</brief_summary>
	<brief_title>A Prospective , Randomized Trial Compare saroGLitazar With pioglitAZone Nonalcoholic Fatty livEr Disease</brief_title>
	<detailed_description>The therapeutic option management nonalcoholic fatty liver disease ( NAFLD ) include lifestyle modification , insulin sensitizer , vitamin E , antioxidant cytoprotective agent . Glitazones insulin sensitize drug act stimulate PPAR gamma receptor . The drug like Pioglitazone Rosiglitazone show conflict result NAFLD trial . Dual PPAR stimulators ( PPAR gamma PPAR alfa ) know `` Glitazars '' useful simultaneously control hyperglycemia , dyslipidemia insulin resistance . Saroglitazar first drug approve investigator country management diabetic dyslipidemia . The investigator plan study efficacy drug comparison Pioglitazone patient NAFLD period 24 week .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Drug naive patient NAFLD diagnose ultrasonography , BMI &gt; 23 kg/m2 ALT &gt; 1.5 time upper limit normal Use drug lifestyle modification NAFLD , HbA1c &gt; 8 % FBS &gt; 200 , Bilirubin &gt; 1.5 mg/dL Any illness likely cause transaminitis positive viral marker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>NAFLD , Diabetes , Glitazone</keyword>
</DOC>